REG - Genus - Appointment of Chief Executive Officer Designate

GenusAnnouncement

03/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230403:nRSC0250Va&default-theme=true

RNS Number : 0250V  Genus PLC  03 April 2023

For Immediate Release
 
                3 April 2023

 

Genus plc

('Genus', or the 'Company')

Appointment of Chief Executive Officer Designate

Genus plc (LSE: GNS), a leading global animal genetics company, announces
that Jorgen Kokke has been appointed by the Board as Chief Executive Officer
Designate with effect from 2 May 2023.

This follows the announcement made on 23 February 2023, that Stephen Wilson
will retire on 30 September 2023.  Jorgen will become Chief Executive Officer
of Genus from 1 July 2023.  From that date, Stephen Wilson will step down
from his role as Chief Executive Officer, but will remain actively involved in
the Company to support the smooth transition of responsibility. Stephen will
deliver the full year results in September and continue in his role as an
executive director until his retirement on 30 September 2023.

Jorgen has deep experience in the international food and agriculture sectors
having spent the last 14 years in global business leadership roles of
increasing responsibility at Ingredion Incorporated, a leading food and
beverage ingredient solutions company, listed on the New York Stock
Exchange.  Most recently, Jorgen was Executive Vice President & President
Americas with responsibility for all operational and strategic management
decisions across its $6 billion North and South American businesses, driving
growth by leveraging research and development led innovation and commercial
and operational excellence.  Prior to his time at Ingredion, Jorgen worked at
CSM NV, another global ingredients company, where he was Vice President of
Food and Nutrition and prior to that, at Unilever.

 

Iain Ferguson, Chairman of Genus, commented on Jorgen's appointment:

"I am delighted to welcome Jorgen to Genus. He is an internationally
experienced business leader with extensive food sector knowledge. Jorgen has
proven international leadership, clear strategic vision, and the ability to
engage and continue to motivate our employees and porcine and bovine
customers.  He is ideally suited to lead Genus through the next stage of our
continued growth, and it is clear that Genus will continue to be in strong
hands.  The Board and I would like to thank Stephen for his ongoing
commitment to the Company and his significant contributions to its success."

 

Jorgen Kokke, designate Chief Executive Officer, responded:

"I am joining Genus because I can see the great potential for the Company,
which is already a global leader in the porcine and bovine genetics market.
I have been consistently impressed by the quality of the people I've met
within the business and the strength of its culture.  I'm excited by Genus's
innovation, which includes its PRRSv resistant pig programme, its global
commercial reach and its world leading product line-up.  I believe Genus has
an exciting future and I will aim to drive forward its many strategic and
growth opportunities, delivering value to our customers, employees and
shareholders. I am also looking forward to working with Stephen Wilson on a
seamless transition and thank him for his continued input."

 

 

 Genus                                        Tel: +44(0)1256 345970
 Iain Ferguson, Chair

Alison Henriksen, Chief Financial Officer
 Buchanan                                     Tel: +44(0)207 466 5000
 Charles Ryland / Chris Lane / Verity Parker

This announcement is available on the Genus website www.genusplc.com
(http://www.genusplc.com/)

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to
animal breeding and genetic improvement by applying biotechnology and sells
added value products for livestock farming and food producers. Its technology
is applicable across livestock species and is currently commercialised by
Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen,
embryos and breeding animals with superior genetics to those animals currently
in farms. Genus's customers' animals produce offspring with greater production
efficiency, and quality, and use these to supply the global dairy and meat
supply chains.

The Group's competitive edge has been created from the ownership and control
of proprietary lines of breeding animals, the biotechnology used to improve
them and its global supply chain, technical service and sales and distribution
network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in
over twenty-five countries on six continents, with research laboratories
located in Madison, Wisconsin, USA.

Regulatory Notes

Details of any payments to be made to Jorgen Kokke will be disclosed in full
in the Company's 2023 Directors' Remuneration Report.  Any such terms will be
consistent with the Company's approved Directors' Remuneration Policy.

 

This announcement is made in accordance with Listing Rule 9.6.11R.   There
are no matters to be disclosed in connection with Listing Rule 9.6.13R (2) -
(6).

 

This announcement contains inside information for the purposes of article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.  The person responsible for making this announcement on behalf of the
Group is Dan Hartley (General Counsel and Company Secretary).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSDLFMFEDSEDD